Pembrolizumab and nivolumab, IgG4 monoclonal antibodies that target PD-1, are currently approved for recurrent/metastatic HNSCC based on well documented efficacy in clinical trials (22, 23). This evidence concerns the gene PDCD1 and head and neck squamous cell carcinoma.